Compile Data Set for Download or QSAR
Report error Found 520 of affinity data for UniProtKB/TrEMBL: P48506
LigandChemical structure of BindingDB Monomer ID 50366432BDBM50366432(CHEMBL1627263)
Affinity DataKi:  390nMAssay Description:Tested for inhibition of Escherichia coli gamma-glutamylcysteine synthetase at a concentration of 5.1 uMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2012
Entry Details Article

LigandChemical structure of BindingDB Monomer ID 50287274BDBM50287274((2S)-2-ammonio-4-[(2-carboxylatobutyl)phosphinato]...)
Affinity DataKi:  4.95E+3nMAssay Description:Tested for inhibition of Escherichia coli gamma-glutamylcysteine synthetase at a concentration of 5.7 uMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2012
Entry Details Article

LigandChemical structure of BindingDB Monomer ID 50287275BDBM50287275(2-ammonio-4-[(2-carboxylatobutyl)sulfonyl]butanoat...)
Affinity DataKi:  9.23E+3nMAssay Description:Tested for inhibition of Escherichia coli gamma-glutamylcysteine synthetase at a concentration of 16.3 uMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2012
Entry Details Article

LigandChemical structure of BindingDB Monomer ID 790533BDBM790533(US20260034094, Compound 169)
Affinity DataIC50: 1.02E+4nMAssay Description:The cell-based assay measures inhibition or reduction of Aβ40 in conditioned medium of test compound treated cells expressing amyloid precursor ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790569BDBM790569(US20260034094, Compound 205)
Affinity DataIC50: 1.90E+4nMAssay Description:The cell-based assay measures inhibition or reduction of Aβ40 in conditioned medium of test compound treated cells expressing amyloid precursor ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790831BDBM790831(US20260034094, Compound 467)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790832BDBM790832(US20260034094, Compound 468)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790829BDBM790829(US20260034094, Compound 465)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790830BDBM790830(US20260034094, Compound 466)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790827BDBM790827(US20260034094, Compound 463)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790825BDBM790825(US20260034094, Compound 461)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790826BDBM790826(US20260034094, Compound 462)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790840BDBM790840(US20260034094, Compound 476)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790838BDBM790838(US20260034094, Compound 474)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790835BDBM790835(US20260034094, Compound 471)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790836BDBM790836(US20260034094, Compound 472)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790834BDBM790834(US20260034094, Compound 470)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790845BDBM790845(US20260034094, Compound 481)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790843BDBM790843(US20260034094, Compound 479)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790841BDBM790841(US20260034094, Compound 477)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790842BDBM790842(US20260034094, Compound 478)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790863BDBM790863(US20260034094, Compound 499)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790864BDBM790864(US20260034094, Compound 500)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790862BDBM790862(US20260034094, Compound 498)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790858BDBM790858(US20260034094, Compound 494)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790871BDBM790871(US20260034094, Compound 507)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790869BDBM790869(US20260034094, Compound 505)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790868BDBM790868(US20260034094, Compound 504)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790865BDBM790865(US20260034094, Compound 501)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790866BDBM790866(US20260034094, Compound 502)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790879BDBM790879(US20260034094, Compound 515)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790877BDBM790877(US20260034094, Compound 513)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790873BDBM790873(US20260034094, Compound 509)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790874BDBM790874(US20260034094, Compound 510)
Affinity DataIC50: 2.00E+4nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790610BDBM790610(US20260034094, Compound 246)
Affinity DataIC50: 2.00E+4nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790612BDBM790612(US20260034094, Compound 248)
Affinity DataIC50: 2.00E+4nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790611BDBM790611(US20260034094, Compound 247)
Affinity DataIC50: 2.00E+4nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790618BDBM790618(US20260034094, Compound 254)
Affinity DataIC50: 2.00E+4nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790617BDBM790617(US20260034094, Compound 253)
Affinity DataIC50: 2.00E+4nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790620BDBM790620(US20260034094, Compound 256)
Affinity DataIC50: 2.00E+4nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790619BDBM790619(US20260034094, Compound 255)
Affinity DataIC50: 2.00E+4nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790614BDBM790614(US20260034094, Compound 250)
Affinity DataIC50: 2.00E+4nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790613BDBM790613(US20260034094, Compound 249)
Affinity DataIC50: 2.00E+4nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790616BDBM790616(US20260034094, Compound 252)
Affinity DataIC50: 2.00E+4nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790615BDBM790615(US20260034094, Compound 251)
Affinity DataIC50: 2.00E+4nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790626BDBM790626(US20260034094, Compound 262)
Affinity DataIC50: 2.00E+4nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790625BDBM790625(US20260034094, Compound 261)
Affinity DataIC50: 2.00E+4nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790622BDBM790622(US20260034094, Compound 258)
Affinity DataIC50: 2.00E+4nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790621BDBM790621(US20260034094, Compound 257)
Affinity DataIC50: 2.00E+4nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

LigandChemical structure of BindingDB Monomer ID 790624BDBM790624(US20260034094, Compound 260)
Affinity DataIC50: 2.00E+4nMAssay Description:For evaluation of the effects of DGAT2 inhibitors in a cell-based setting, cryopreserved human hepatocytes (Lot QOC, Celsis, Chicago, Ill.) were thaw...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/18/2026
Entry Details US Patent

Displayed 1 to 50 (of 520 total ) | Next | Last >>
Jump to: